Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint ...Middle East

SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...

Hence then, the article about innovent announces phase 2 clinical study of picankibart ibi112 in chinese patients with ulcerative colitis met primary endpoint was published today ( Thursday 17/10/2024 - 03:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint )

Also on site :

• Art Garfunkel Makes Surprise Return to Madison Square Garden with Charlie Puth in Special Performance of "The Boxer"
• ‘The Birds’ Limited Series Starring Sarah Snook Hits TV Marketplace; New Take On Hitchcock’s Classic Comes From Tom Spezialy, David Heyman & UIS
• The Coronation Of Santa Maria’s 2026 Rodeo Queen